Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.
Cancer. 2011 Sep 1;117(17):3889-99. doi: 10.1002/cncr.25935. Epub 2011 Feb 24.
Currently, nonsmall-cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. Angiogenesis, the formation of new vasculature, is a complex and tightly regulated process that promotes metastasis and disease progression in lung cancer and other malignancies. Developmental antiangiogenic agents have shown activity in NSCLC, and bevacizumab, an antiangiogenic monoclonal antibody, is approved for the treatment of patients with advanced disease. However, predictive biomarkers are needed to guide the administration of antiangiogenic agents. It is possible that angiogenic molecules could accurately predict patient response to targeted antiangiogenic therapies, which would allow individualized and perhaps more effective treatment. Angiogenic signaling molecules may also have value as prognostic indicators, which may be useful for the management of NSCLC. Here the author provides an overview of angiogenic molecules currently being investigated as prognostic biomarkers in NSCLC and discusses their potential to guide treatment choices.
目前，非小细胞肺癌（NSCLC）是美国癌症相关死亡的主要原因。血管生成是新血管形成的复杂和严格调节的过程，促进肺癌和其他恶性肿瘤的转移和疾病进展。发育性抗血管生成药物在 NSCLC 中显示出活性，贝伐单抗是一种抗血管生成的单克隆抗体，被批准用于治疗晚期疾病。然而，需要预测生物标志物来指导抗血管生成药物的应用。血管生成分子可能能够准确预测患者对靶向抗血管生成治疗的反应，这将允许进行个体化和可能更有效的治疗。血管生成信号分子也可能具有作为预后指标的价值，这可能对 NSCLC 的管理有用。作者在这里概述了目前作为 NSCLC 预后生物标志物进行研究的血管生成分子，并讨论了它们指导治疗选择的潜力。
